Patents by Inventor Sha-Sha Wang

Sha-Sha Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210087632
    Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.
    Type: Application
    Filed: October 8, 2019
    Publication date: March 25, 2021
    Inventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
  • Patent number: 10443099
    Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: October 15, 2019
    Assignee: Becton, Dickinson and Company
    Inventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
  • Publication number: 20190256893
    Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 22, 2019
    Inventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
  • Patent number: 10323267
    Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: June 18, 2019
    Assignee: Becton Dickinson and Company
    Inventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
  • Patent number: 10190152
    Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: January 29, 2019
    Assignee: Becton, Dickinson and Company
    Inventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
  • Patent number: 9499858
    Abstract: A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: November 22, 2016
    Assignee: Becton, Dickinson and Company
    Inventors: James G. Nadeau, Tobin Hellyer, Dolores M. Berger, William Nussbaumer, Robert Rosenstein, Andrew Kuhn, Sha-Sha Wang, Keith Edward Thornton
  • Publication number: 20160194687
    Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.
    Type: Application
    Filed: March 11, 2016
    Publication date: July 7, 2016
    Applicant: Becton, Dickinson and Company
    Inventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
  • Publication number: 20160168638
    Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.
    Type: Application
    Filed: September 10, 2015
    Publication date: June 16, 2016
    Inventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
  • Publication number: 20150152473
    Abstract: A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.
    Type: Application
    Filed: January 11, 2013
    Publication date: June 4, 2015
    Applicant: BECTON, DICKINSON AND COMPANY
    Inventors: James G. Nadeau, Tobin Hellyer, Dolores M. Berger, William Nussbaumer, Robert Rosenstein, Andrew Kuhn, Sha-Sha Wang, Keith Edward Thornton
  • Publication number: 20140141435
    Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.
    Type: Application
    Filed: August 12, 2013
    Publication date: May 22, 2014
    Applicant: Beckton, Dickinson and Company
    Inventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
  • Patent number: 8372605
    Abstract: A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: February 12, 2013
    Assignee: Becton, Dickinson and Company
    Inventors: James Nadeau, Tobin J. Hellyer, Dolores M. Berger, William Nussbaumer, Robert Rosenstein, Andrew Kuhn, Sha-Sha Wang, Keith Edward Thornton
  • Patent number: 8323929
    Abstract: The invention employs an unlabeled signal primer comprising a 5? adapter sequence for detection of variations in nucleic acid target sequences. The detection system further comprises a reporter probe, the 3? end of which hybridizes to the complement of the 5? adapter sequence of the signal primer to produce a 5? overhang. Polymerase is used to fill in the overhang and synthesize the complement of the 5? overhang of the reporter probe. Synthesis of the reporter probe complement is detected, either directly or indirectly, as an indication of the presence of the target.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: December 4, 2012
    Assignee: Becton, Dickinson and Company
    Inventors: Sha-Sha Wang, Keith Thornton, James G. Nadeau, Tobin J. Hellyer
  • Publication number: 20110244457
    Abstract: A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.
    Type: Application
    Filed: March 25, 2011
    Publication date: October 6, 2011
    Applicant: Becton, Dickinson and Company
    Inventors: James Nadeau, Tobin Hellyer, Dolores M. Berger, William Nussbaumer, Robert Rosenstein, Andrew Kuhn, Sha Sha Wang, Keith Thornton
  • Publication number: 20110105350
    Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.
    Type: Application
    Filed: May 7, 2010
    Publication date: May 5, 2011
    Inventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
  • Patent number: 7932060
    Abstract: A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.
    Type: Grant
    Filed: April 19, 2004
    Date of Patent: April 26, 2011
    Assignee: Becton, Dickinson and Company
    Inventors: James Nadeau, Tobin Hellyer, Dolores Berger, William Nussbaumer, Robert Rosenstein, Andrew Kuhn, Sha Sha Wang, Keith Thornton
  • Publication number: 20110059455
    Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.
    Type: Application
    Filed: September 2, 2010
    Publication date: March 10, 2011
    Applicant: BECTON, DICKINSON AND COMPANY
    Inventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
  • Patent number: 7767395
    Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: August 3, 2010
    Assignee: Becton, Dickinson and Company
    Inventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
  • Publication number: 20090246792
    Abstract: The invention employs an unlabeled signal primer comprising a 5? adapter sequence for detection of variations in nucleic acid target sequences. The detection system further comprises a reporter probe, the 3? end of which hybridizes to the complement of the 5? adapter sequence of the signal primer to produce a 5? overhang. Polymerase is used to fill in the overhang and synthesize the complement of the 5? overhang of the reporter probe. Synthesis of the reporter probe complement is detected, either directly or indirectly, as an indication of the presence of the target.
    Type: Application
    Filed: April 7, 2009
    Publication date: October 1, 2009
    Applicant: Becton, Dickinson and Company
    Inventors: Sha-Sha WANG, Keith Thornton, James G. Nadeau, Tobin J. Hellyer
  • Publication number: 20060246495
    Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.
    Type: Application
    Filed: April 14, 2006
    Publication date: November 2, 2006
    Inventors: James Garrett, Sha-Sha Wang, Keith Thornton, Richard Moore, William Keating, William Nussbaumer, Craig Whiteford
  • Patent number: 6682889
    Abstract: Amplification primers and methods for specific amplification and detection of a rnpB gene sequence are disclosed. The primer-target binding sequences are useful for amplification and detection of organisms of the Chlamydiaceae family in a variety of amplification and detection reactions.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: January 27, 2004
    Assignee: Becton, Dickinson and Company
    Inventors: Sha-Sha Wang, David Wolfe